Open AccessEarly-onset Cardiotoxicity assessment related to anthracycline in children with leukemia. A Prospective Study
Author(s) -
Adriana Linares Ballesteros,
Roy Sanguino Lobo,
Juan Camilo Villada Valencia,
Oscar Arévalo Leal,
Darwin Hernández,
Nelson Aponte Barrios,
Iván Perdomo Ramírez
Publication year - 2020
Publication title -
colombia medica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.455
H-Index - 18
eISSN - 1657-9534
pISSN - 0120-8322
DOI - 10.25100/cm.v52i1.4542
Subject(s) - cardiotoxicity , medicine , anthracycline , leukemia , prospective cohort study , oncology , chemotherapy , cancer , breast cancer
Background:Acute leukemias are the most frequent malignancies in children. Advances in treatment have improved the overall survival to 80%. Almost 10% of children with cancer develop clinical cardiac toxicity. Total anthracycline cumulative dose is a risk factor for early-onset cardiotoxicity.Objective:To describe the incidence of early-onset cardiotoxicity in children with acute leukemia treated with chemotherapy.Methods:A prospective descriptive study of patients >1 y and <18 years diagnosed with acute leukemia. Assessed with electrocardiogram, echocardiography, and blood biomarkers at diagnosis and during the follow-up.Results:94 patients with acute lymphoblastic leukemia and 18 with acute myeloid leukemia were included. 20 patients (17.9%) developed early-onset cardiotoxicity. Statistically significant data was seen after anthracycline dose >150 mg/m2, between the first echocardiographic evaluation and posterior analyses in the left ventricular fraction ejection with Teicholz p 0.05, Simpson p 0.018 and GLS p 0.004. In this study, there was no relation between blood biomarkers and cardiotoxicity.Conclusions:Cancer therapeutic-related cardiac dysfunction is related to anthracycline cumulative dose. In this study, echocardiographic follow-up was useful to predict risk factors for early cardiac dysfunction.